News

The FDA accepted an investigational new drug application allowing for the start of a phase 1 trial to evaluate the tolerability of AVB-101 in patients with platinum resistance ovarian cancer.

High objective response and complete response rates observed with mosunetuzumab in patients with relapsed/refractory follicular lymphoma.

In an interview with Targeted Oncology, Christopher Nevala-Plagemann, MD, discussed the key takeaways of his research on the best treatment strategies for patients with left sided RAS or RAF wild-type metastatic colorectal cancer.

Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.

Disparities exist for Medicaid-insured patients at centers designated for high-quality care, according to researchers from Yale Cancer Center.

The LYNK-003 trial evaluating olaparib monotherapy or in combination with bevacizumab in patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction has ended due to futility.

High-dose REGN5678 combined with cemiplimab shows preliminary response elicitation in patients with metastatic castration-resistant prostate cancer.

Favorable overall survival results were shown with preoperative combination chemotherapy in patients with pancreatic cancer.

Frontline treatment with ibrutinib, bendamustine, and rituximab showed a prolongation in progression-free survival along with a good response rate in older patients with mantle cell lymphoma.

Michael Wang, MD, gives a brief overview of the safety and efficacy findings of a phase 1b study evaluating acalabrutinib plus venetoclax and rituximab in patients with mantle cell lymphoma.

The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.

The phase 3 TAVT45CO2 study investigating TAVT-45 in patients with metastatic castrate-sensitive prostate cancer and metastatic castrate-resistant prostate cancer has finished enrollment.

Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.

Robert J. Soiffer, MD, discusses the use of stem cell transplant in treating hematologic malignancies prior to the availability of chimeric antigen receptor T-cell products.

In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.

Pivotal phase 3 result have led the FDA to accept a biologics license applications for omidubicel as treatment of patients with blood cancers requiring allogenic hematopoietic stem cell transplant. The applications has been accepted for priority review.

A phase 1/2 clinical trial examining the combination of afuresertib, sintilimab, and chemotherapy in patients with specific solid tumors who were resistant to anti-PD-1/PD-L1 therapy has dosed its first patient.

Florida Cancer Specialists & Research Institute, LLC welcomes four Board-certified medical oncologists to the statewide practice, expanding care for patients receiving treatment for cancer and blood disorders. Joining FCS on August 1, 2022 are Mohammad Jahanzeb, MD, FACP, Tony J. Kurian, MD, Susan K. Morgan, MD and Wenqing Zhang, MD, PhD.

Marcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.

The phase 3 INTERLINK-1 study of monalizumab and cetuximab as treatment of recurrent or metastatic squamous cell carcinoma of the head and neck has been discontinued. The study did not meet its efficacy goal.

Advanced machine learning and natural language processing approaches were combined to identify patients with non-metastatic castration-resistant prostate cancer from electronic health records data.

In an interview with Targeted Oncology, Lori Wirth, MD, discussed the evolving treatment landscape for NTRK fusion-positive thyroid cancers.

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer.

A look back at all of the FDA happenings of July 2022.

In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.

Sarah C. Rutherford, MD, discussed how findings from her research could impact the current guidelines for follicular lymphoma.

The FDA has accepted the biologics license application for N-803 as a treatment for patients with Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

Mature survival data from the phase 3 ICON8 trial revealed no significant difference between administering weekly dose-dense chemotherapy and standard 3-weekly chemotherapy as front-line therapy for patients with epithelial ovarian cancer.

In the phase 3 CheckMate-914 clinical trial, the combination of nivolumab and ipilimumab did not achieve its primary end point of improvement in disease-free survival compared with the placebo control.

Mariuxi Viteri Malone, MD, has joined Florida Cancer Specialists & Research Institute.